Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Key claim: The DEA proposes to temporarily place 7-hydroxymitragynine above a specified concentration threshold in Schedule I of the Controlled Substances Act, imposing full Schedule I regulatory controls on its manufacture, distribution, possession, and related activities.
Abstract
(Proposed Rule · Justice Department, Drug Enforcement Administration) The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine above a specified threshold, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 7-hydroxymitragynine above a specified threshold.
Why this matters
This proposed rule marks the first federal move to directly schedule 7-hydroxymitragynine, the potent kratom alkaloid at the center of concentrated kratom-extract and consumer product concerns. If finalized, products exceeding the DEA’s threshold would face Schedule I prohibitions affecting manufacturers, retailers, researchers, and consumers of kratom-derived goods. The threshold-based approach also signals a regulatory strategy of targeting concentrated/synthetic forms while leaving lower-concentration kratom leaf products in a different posture.